Bone Involvement in Pediatric Acute Myeloid Leukemia: What can we Currently Infer?
International Journal of Research and Reports in Hematology,
Page 1-9
Abstract
Introduction: Acute myeloid leukemia (AML) is a clonal disease of the hematopoietic tissue characterized by abnormal proliferation of myeloid lineage progenitor cells, resulting in insufficient generation of normal mature blood cells.
Bone pain is often present at the diagnosis of pediatric acute lymphoblastic leukemia but is very rare in acute myeloid leukemia. It may also indicate the presence of pathological fracture, lytic lesions, arthritis, or associated osteitis, which may delay diagnosis.
Objective: To study the incidence of children with acute myeloid leukemia (AML) with bone involvement. Clinico-biological description and analysis of the prognostic impact of age, sex, treatment, type of bone involvement associated with acute myeloid leukemia.
Methodology: This partly prospective/retrospective descriptive study included 17 children with AML diagnosed at the Department of Hematology and Pediatric Oncology CHU Mohamed VI Marrakech Morocco, during the period from March 2011 to November 2021. A form gathering the main items necessary for the study was made for 17 cases.
Results: In order to describe the bone involvement (BA) in pediatric AML, we reviewed the records of 47 patients followed in our unit for AML. The overall incidence of OA was 36.17% or 17 cases. At diagnosis, patients had a revealing AO in 47.05% of cases, i.e. 8 cases, one of which, the diagnosis of AML was delayed by 6 months. During and after treatment, respectively 23.5% and 29.4% of patients presented bone complications (bone pain, vertebral compression, osteolysis).
The average age of the patients with AO was 8.5 years. A predominance of female gender at 52.94% (9 cases).
In our study, the majority of AO were resolved after AML treatments without short-term sequelae. However, a death rate was marked at 58.80% (10 cases).
Keywords:
- Acute myeloid leukemia
- bone involvement
- chemotherapy
- child
How to Cite
References
Tragiannidis A, Vasileiou E, Papageorgiou M, et al. Bone involvement at diagnosis as a predictive factor in children with acute lymphoblastic leukemia.Hippokratia. 2016;20:227–230.
Cooper TM, Hasle H, Smith FO. Acute myeloid leukemia, mye-loproliferative, and myelodysplastic disorders. In: Pizzo PA.
Martins SL, Falcão RP. The importance of immunophenotyping in acute myeloid leukemia. Rev Assoc Med Bras. 2000;46:57-21.
Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Pediatric clinics of North America. 2008 Feb 1;55(1):21-51.
LahlouI Z, Lafhel K, Maani J, Hachim A. Leucémiesaigues de l’enfant: étude de 142 cas. Archives de Pédiatrie. 2014; 21:357.
Hafiz MG, Islam A, Siddique R, et al. Back painand vertebral compression: an unusual presentationof childhood acute lymphoblastic leukemia. Mymensingh Med J. 2010;19:130-136.
Santangelo JR, Thomson JD. Childhood leukemiapresenting with back pain and vertebral compression fractures. Am J Orthop. 1999;28:257-260.
Shahnazi M, Khatami A, Shamsian B, et al. Bonylesions in pediatric acute leukemia: pictorial essay.Iran J Radiol, 2012;9:50-56.
Salim H, Ariawati K. Osteoporosis resulting from acute lymphoblastic leukemia in a 7-year-old boy:a case report. J Med Case Report. 2014;8:168.
Kunstreich M. Osteonecrosis in children withacute lymphoblastic leukemia. Haematologica. 2016;101:1295–1305.
Mostoufi-Moab S, Halton J. Bone morbidity inchildhood leukemia: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep. 2014;12:300– 312.
Niinimaki RA, Harila-Saari AH, Jartti AE, Seuri RM, Riikonen PV, Paakko EL, Mottonen MI, Lanning M. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. Journal of Clinical Oncology. 2007 Apr 20;25(12):1498-504.
Martins SL, Falcão RP. The importance of immunophenotyping in acute myeloid leukemia. Rev Assoc Med Bras. 2000;46:57-62.
Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Pedi-atr Clin North Am. 2008;55:21---51.
Pereira WV. Acute myelocytic leukemia of childhood and adolescence. Fracassos e vitórias. Rev Bras Hematol Hemoter.2006;28:239---41.
Cristofani LM. Acute Myeloid Leukemia. 1 ed. In: Filho VOJr, Maluf PT, Cristofani LM, Almeida MTA, Teixeira RAP, edi-tors. Doenc¸as neoplásicas da crianc¸a e do adolescente. Barueri: Manole. 2012; 81-7.
Zanichelli AA, Cistófani LM, Almeida MT, Maluf Júnior PT, FilhoVO. Perspectives for acute myeloid leukemia in childhood after observation of a group of conventionally treated patients. Rev Bras Hematol Hemoter. 2006;28:246-52.
Xu XJ, Tang YM, Song H, Yang SL, Shi SW, Wei J. Long-termoutcome of childhood acute myeloid leukemia in a developingcountry: experience from a children’s hospital in China. Leuk.Lymphoma. 2010;51:2262-9.
Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia:towards high-quality cure of all patients. Haematologica. 2007;92:1519-32.
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S. Children’sOncology Group’s 2013 Blueprint for Research: acute myeloidleukemia. Pediatr Blood Cancer. 2013;60:964-71.
Viana MB, Cunha KC, Ramos G, Murao M. Acute myeloid leukemia in children: a 15-year experience at a single Institution. J Pediatr (Rio J). 2003;79:489-96.
Nouvelles approches dans le traitement des leucémies aiguës de l'enfant Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse Hôpital Debrousse 29, rue Sœur-Bouvier 69322 Lyon cedex 05, France
Vincent F, Hospital MA, Lemiale V, Bruneel F, Darmon M, Gonzalez F, Kouatchet A, Mokart D, Pène F, Rabbat A, Cohen Y. Therapeutic management of pulmonary manifestations in the acute phase of acute myeloblastic leukemia. Review of respiratory diseases. 2012 Jun 1;29(6):743-55..
Binger CM, Ablin AR, Feuerstein RC, Kushner JH, Zoger S, Mikkelsen C. Childhood leukemia. New England Journal of Medicine. 1969 Feb 20;280(8): 414-8.
Creutzig U, Heuvel-Eibrink MM, Gibson B, Dworzak MN, AdachiS, Bont E. Diagnosis and management of acute myeloid leu-kemia in children and adolescents: recommendations from aninternational expert panel. Blood. 2012;120:3187- 205.
Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with paediatric acute mye-loid leukaemia treated according to the AML99 protocol in theperiod 2003-06 from the Japan Association of Childhood Leuka-emia Study. Br J Haematol. 2012;159:204-10.
Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br JHaematol. 2012;159:259-87.
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, HeineckeA, et al. Early blast clearance by remission induction therapyis a major independent prognostic factor for both achievementof complete remission and long-term outcome in acute mye-loid leukemia: Data from the Germa AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64-70.
Pinheiro RF, Pelloso LA, Yamamoto M, Chauffaille ML, BordimJA. Atra syndrome: 2 years experience. Rev. Bras. Cancerol. 2003;49:27-31.
Tarlock K, Meshinchi S. Pediatric acute myeloid leucemia: bio-logy and therapeutic implications of genomic variants. PediatrClin North Am. 2015;62:75-93.
-
Abstract View: 40 times
PDF Download: 23 times
